CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:56:06 2024-04-25 am EDT			5-day change	1st Jan Change
3.76 ^SEK	-1.05%		-2.34%	+39.78%

Mar. 13	CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	CI
Feb. 21	Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	CI

New issue of CombiGene's newsletter Ingeneious!

February 23, 2022 at 07:31 am EST

Read CombiGene’s newsletter in English here or download the attachement

Contact
Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)8 52 80 03 99, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Latest news about CombiGene AB

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	Mar. 13	CI
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	Feb. 20	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project	Nov. 01	MT
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project	23-10-31	CI
CombiGene, Zyneyro to Start Clinical Studies of COZY01 Targeting Shingles	23-10-26	MT
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project	23-10-26	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
CombiGene CEO to Depart in September	23-06-30	MT
CombiGene AB Announces Chief Executive Officer Changes	23-06-30	CI
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs	23-05-24	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-17	CI
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain	23-01-09	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Combigene AB Appoints Peter Ekolind as COO	22-09-27	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
CombiGene AB Signs Agreement with A Potential Value of USD 328.5 Million with Spark Therapeutics	22-02-21	CI
CombiGene AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-17	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-17	CI
Combigene AB Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study	22-01-17	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI

Chart CombiGene AB

Duration

Period

More charts

Company Profile

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-17 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COMBIGENE AB	+39.78%	6.91M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs